Calls for papers
-
Device maker H&T Presspart has announced the opening of a new laboratory scale facility at its Blackburn, UK Inhalation Product Technology Centre (IPTC) for filling metered dose inhalers with lower global warming potential (GWP) propellants, including… Read more . . .
-
Padagis, formerly Perrigo’s generic prescription pharmaceutical business, has announced the launch of a generic version of Narcan naloxone nasal spray for the reversal of opioid overdose. The Padagis generic is the second approved in the… Read more . . .
-
Glenmark Pharmaceuticals has announced the launch of an inhaled dry powder fixed dose combination of indacaterol and mometasone furoate for the treatment of asthma which is being marketed under the name “Indamet”. All three of… Read more . . .
-
Savara announced that the UK Medicines and Healthcare Products Regulatory Agency has awarded an Innovation Passport to molgramostim inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). The Innovation… Read more . . .
-
Acorda Therapeutics announced that Inbrija levodopa inhalation powder has been launched in Germany by Esteve Pharmaceuticals. The EMA approved Inbrija DPI for the treatment of OFF periods in Parkinson’s disease in 2019. Acorda said that… Read more . . .
-
Adherium has announced that Helicon Health, a spin out from the UCL Centre for Health Informatics and Multi Professional Education, will market Adherium’s Hailie inhaler sensors and monitoring service in the UK. According to the… Read more . . .
-
Oragenics has published data from studies of its NT-CoV-2-1 proteosome adjuvanted intranasal vaccine candidate against SARS-CoV-2 in mice and hamsters that support further development of the vaccine, the company said. The data were published June… Read more . . .
-
Optinose has announced that the Phase 3 ReOpen2 trial of Xhance fluticasone propionate nasal spray (OPN-375) in patients with chronic sinusitis without nasal polyps demonstrated significant improvement compared to placebo in both patient reported symptoms at… Read more . . .
-
Posted on OINDPnews on June 9, 2022Company: ModernaLocation: Norwood, MA, USA The Role:This role is an exciting opportunity to be a critical part of a team enabling respiratory delivery of mRNA at an organization that is radically… Read more . . .
-
According to CounterAct, the Canadian Intellectual Property Office has issued a patent (3065307, “Prescription bottle cap capable of administering opioid overdose reversal agent”) covering the company’s naloxone nasal spray cap. CounterAct co-founder Todd Pizitz commented, “We are pleased… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland